Diamondback Drugs is recalling 8,068 units of Buprenorphine HCL PF (C) Injectable, a veterinary pain medication, due to long-term stability issues. This defect means the medication may not provide the expected level of pain relief for animals. This recall affects two strengths (0.15 mg/ml and 0.6 mg/ml) of the compounded injectable product sold nationwide. Owners and veterinarians should stop using these specific lots immediately to ensure animals receive proper therapeutic care.
The product suffers from long-term stability issues, which can cause the medication to lose its potency over time. This means an animal in pain may not receive the necessary therapeutic relief, leading to prolonged suffering or ineffective treatment following veterinary procedures.
Contact your healthcare provider or pharmacist for guidance. Return any unused product to the pharmacy for a refund
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response